Efficacy and Tolerability of a Combined Moxifloxacin/Dexamethasone Formulation for Topical Prophylaxis in Phacoemulsification: An Open-Label Single-Arm Clinical Trial

Table 2

Ocular signs of inflammation observed in eyes, n (%).

	Baseline	Day 1	Day 3	Day 8	Day 15
Eyelid and conjunctiva
0	64 (100.0%)	58 (90.6%)	61 (95.3%)	63 (98.4%)	63 (98.4%)
1	0 (0.0%)	6 (9.4%)	3 (4.7%)	1 (1.6%)	1 (1.6%)
Cornea
0	64 (100.0%)	49 (76.6%)	57 (89.1%)	62 (96.9%)	62 (96.9%)
1	0 (0.0%)	15 (23.4%)	7 (10.9%)	2 (3.1%)	2 (3.1%)

0 = No evidence of active inflammatory signs or significant structural changes or discharge.
1 = Presence of active inflammation signs or significant structural change or discharge.